 The FDA has placed a clinical hold on LogicBio Therapeutics Incs NASDAQ: LOGC Phase 12 SUNRISE trial of LB-001 in pediatric patients with methylmalonic acidemia MMA. The hold follows after two adolescent patients in the trial were diagnosed with thrombotic microangiopathy TMA, a clinical syndrome defined by the formation of tiny clots in blood vessels. 